news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

Eisai Inc

Lynn D. Kramer, MD
Lynn D. Kramer, M.D., is the President of the Eisai Neuroscience Product Creation Unit, where he oversees the full product creation cycle, including licensing activities, from discovery through regulatory approval of innovative projects in the neuroscience area.  Prior to his employment at Eisai, he had positions in a number of pharma companies, large and small, during his 23 year industry career including PAR Pharmaceutical, Inc., Purdue Pharmaceuticals, Ciba Geigy, Novartis, the R.W. Johnson Pharmaceutical Research Institute, and Carter-Wallace, Incorporated. During his career he has lead teams and groups accounting for 17 NDAs and has been responsible for leading the Neuroscience Therapeutic Area Strategy Team at Ciba and Novartis, which included discovery research, clinical development, and global marketing. He is a Fellow of the American Board of Psychiatry and Neurology (1987).  He has had multiple grants and has been CO-Prinicipal Investigator on a large NIH-sponsored Program Project and other projects. He has more than 90 publications (chapters, journal articles, abstracts). He received his M.D. from Hahnemann Medical College, completed his internship in Internal Medicine at the University of California at Irvine and his residency in Neurology at the University of Virginia. 

The Eisai Neuroscience Product Creation Unit
The Eisai Neuroscience Product Creation Unit was established in 2009 when Eisai designated integrative neuroscience as a therapeutic area of focus.  The unit has major research facilities in Hatfield, UK, Woodcliff Lake, NJ, and Tsukuba, Japan that are engaged in developing innovative new drugs to satisfy unmet medical needs worldwide.   Eisai has been committed to the therapeutic area of neurology for more than a decade, developing products that have been approved for Alzheimer’s disease and epilepsy.  Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). For more information about Eisai, please visit 

Share This Information